Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT
We present the case of an 87-year-old man with a history of prostatic adenocarcinoma
diagnosed in 2006 and initially treated locally with high intensity focused ultrasound. An increase …
diagnosed in 2006 and initially treated locally with high intensity focused ultrasound. An increase …
Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle
…, C Cilliers, GM Thurber, Z Wimana… - Clinical …, 2019 - Wiley Online Library
Precision medicine aims to use patient genomic, epigenomic, specific drug dose, and other
data to define disease patterns that may potentially lead to an improved treatment outcome. …
data to define disease patterns that may potentially lead to an improved treatment outcome. …
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors
Post-transcriptional modifications of RNA constitute an emerging regulatory layer of gene
expression. The demethylase fat mass- and obesity-associated protein (FTO), an eraser of N 6 -…
expression. The demethylase fat mass- and obesity-associated protein (FTO), an eraser of N 6 -…
Imaging diagnostic and therapeutic targets: human epidermal growth factor receptor 2
…, EGE De Vries, K Jhaveri, Z Wimana - Journal of Nuclear …, 2016 - Soc Nuclear Med
Since the approval of trastuzumab, a humanized monoclonal antibody against the
extracellular domain of human epidermal growth factor receptor 2 (HER2), 3 other HER2-targeting …
extracellular domain of human epidermal growth factor receptor 2 (HER2), 3 other HER2-targeting …
[HTML][HTML] A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours
G Marin, B Vanderlinden, I Karfis, T Guiot, Z Wimana… - Physica Medica, 2018 - Elsevier
Purpose Peptide receptor radionuclide therapy with 177 Lu-DOTATATE has become a
standard treatment modality in neuroendocrine tumours (NETs). No consensus has yet been …
standard treatment modality in neuroendocrine tumours (NETs). No consensus has yet been …
[HTML][HTML] Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy
…, J Derrien, GE Ghanem, P Flamen, Z Wimana - International journal of …, 2022 - mdpi.com
Radionuclide Therapy (RNT) with 177 Lu-DOTATATE targeting somatostatin receptors (SSTRs)
in neuroendocrine tumours (NET) has been successfully used in routine clinical practice…
in neuroendocrine tumours (NET) has been successfully used in routine clinical practice…
[HTML][HTML] Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
M Mileva, EGE de Vries, T Guiot, Z Wimana… - NPJ Breast …, 2024 - nature.com
… Zéna Wimana … Zéna Wimana … Zéna Wimana …
68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy
…, P Flamen, F Charlier, H Levillain, Z Wimana… - World journal of …, 2019 - Springer
Purpose The aim of this communication was to assess the efficacy of directed oligometastatic
radiotherapy (RT) based on 68 Ga-PSMA PET/CT in patients with prostate cancer (PCa) …
radiotherapy (RT) based on 68 Ga-PSMA PET/CT in patients with prostate cancer (PCa) …
[HTML][HTML] Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
G Marin, B Vanderlinden, I Karfis, T Guiot, Z Wimana… - EJNMMI physics, 2017 - Springer
Background In order to obtain a reliable 177 Lu-DOTATATE therapy dosimetry, it is crucial
to acquire accurate and precise activity measurements with the radionuclide calibrator, the …
to acquire accurate and precise activity measurements with the radionuclide calibrator, the …
Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu] Lu-DOTATATE in a panel of cancer cell lines
…, GE Ghanem, I Karfis, P Flamen, Z Wimana - Nuclear medicine and …, 2021 - Elsevier
Introduction [ 177 Lu]Lu-DOTATATE is an effective systemic targeted radionuclide therapy
for somatostatin receptor (SSTR) positive metastatic or inoperable neuroendocrine tumours (…
for somatostatin receptor (SSTR) positive metastatic or inoperable neuroendocrine tumours (…